Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

OBJECTIVE: Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies. However, the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells, thus making some patients inel...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lu, Zhou, Jian, Li, Linlin, Zhou, Keshu, Zhao, Lingdi, Zhu, Xinghu, Yin, Qingsong, Li, Yufu, You, Hongqin, Zhang, Jishuai, Song, Yongping, Gao, Quanli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610157/
https://www.ncbi.nlm.nih.gov/pubmed/34390235
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610157/
https://www.ncbi.nlm.nih.gov/pubmed/34390235
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0040

Ejemplares similares